Search

Displaying results 1201 - 1210 of 10000 in total
  1. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    [L34650] Obeticholic acid is currently being considered for FDA approval to treat fibrosis caused by non-alcoholic liver steatohepatitis (NASH). … hepatic decompensation) due to a risk of liver failure, in some cases requiring liver transplantation.

  2. Drug

    Oxaprozin

    go.drugbank.com/drugs/DB00991
    Approved

    Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic
  3. Drug

    Coal tar

    go.drugbank.com/drugs/DB11082
    Approved

    Coal tar is among the by-products when coal is carbonized to make coke or gasified to make coal gas. … It has been indicated for local relief of itching, dryness, and irritation caused by psoriasis, seborrhea and eczema.

    Mixtures: Medi-dan ShampooProducts: Psoriasin Deep Moisturizing 4 oz.
  4. Drug

    Rifampin

    go.drugbank.com/drugs/DB01045
    ApprovedInvestigational

    [A263768] Rifampin is used to treat tuberculosis and works by inhibiting the microbial DNA-dependent RNA polymerase (RNAP).[A263768]

    Mixtures: AKURIT-Z KID DISPERSIBLE TABLETSSynonyms: 5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate
  5. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. … [L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test.

  6. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting

  7. Drug

    Omega-3 fatty acids

    go.drugbank.com/drugs/DB11133
    ApprovedInvestigationalNutraceutical

    α-linolenic acid (ALA) (found in plant oils), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (both commonly found in fish oil that originally come from microalgae that is further consumed by

    Synonyms: n-3 PUFAs, n-3 fatty acidsMixtures: Prenatal Vitamin No 53 Iron Fum Folic Acid Docusate CA DHA, UltimateCare ONE NF
  8. Drug

    Tedizolid

    go.drugbank.com/drugs/DB14569
    ApprovedInvestigational

    [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).

  9. Drug

    Dinoprostone

    go.drugbank.com/drugs/DB00917
    ApprovedInvestigational

    It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts.

    Synonyms: (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate, (5Z,11α,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
  10. Drug

    Repaglinide

    go.drugbank.com/drugs/DB00912
    ApprovedInvestigational

    Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents.